The US Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr.’s revamped Centers for Disease Control and Prevention (CDC) vaccine advisory committee will meet later this month to discuss revised guidelines for the use of respiratory syncytial virus (RSV) vaccines in high-risk adults aged 18-49 years.
The new panel includes several members who have expressed anti-vaccine sentiments or opposed mRNA technology, which underpins Moderna’s approved RSV vaccine, mResvia. The FDA recently approved broader use of mResvia for respiratory syncytial virus in adults aged 18-59 years, paving the way for potential expansion to younger age groups.
The CDC currently recommends RSV vaccination only for adults 75 and older, with a narrower application for those aged 60-74 who are at increased risk. However, the HHS Secretary recently revamped the committee, replacing 17 members with new appointees who have documented histories of vaccine skepticism or opposed mRNA technology.
Analysts expect the CDC’s next meeting to be closely watched by investors, who will see how the refreshed Advisory Committee on Immunization Practices (ACIP) makes recommendations. The key concern is whether the new panel expands mResvia’s use to younger patients, given its approval for adults aged 18-59 years.
Source: https://www.biospace.com/fda/moderna-wins-expanded-label-for-mrna-rsv-shot-as-new-acip-members-question-mrna-technology